NZ576569A - Ketoconazole enantiomer in humans - Google Patents
Ketoconazole enantiomer in humansInfo
- Publication number
- NZ576569A NZ576569A NZ576569A NZ57656907A NZ576569A NZ 576569 A NZ576569 A NZ 576569A NZ 576569 A NZ576569 A NZ 576569A NZ 57656907 A NZ57656907 A NZ 57656907A NZ 576569 A NZ576569 A NZ 576569A
- Authority
- NZ
- New Zealand
- Prior art keywords
- ketoconazole
- enantiomer
- patient
- levels
- administration
- Prior art date
Links
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical class C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 title description 9
- XMAYWYJOQHXEEK-ZEQKJWHPSA-N (2S,4R)-ketoconazole Chemical class C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@H]1O[C@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-ZEQKJWHPSA-N 0.000 claims abstract description 156
- 239000003814 drug Substances 0.000 claims abstract description 38
- 206010061218 Inflammation Diseases 0.000 claims abstract description 21
- 230000004054 inflammatory process Effects 0.000 claims abstract description 21
- 230000009885 systemic effect Effects 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 230000009467 reduction Effects 0.000 claims description 33
- 206010012601 diabetes mellitus Diseases 0.000 claims description 21
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 12
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 10
- 229960004125 ketoconazole Drugs 0.000 description 60
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 50
- 108010074051 C-Reactive Protein Proteins 0.000 description 42
- 102100032752 C-reactive protein Human genes 0.000 description 41
- 229940079593 drug Drugs 0.000 description 35
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 32
- 230000000694 effects Effects 0.000 description 28
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 26
- 238000011282 treatment Methods 0.000 description 26
- 238000000034 method Methods 0.000 description 23
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 16
- 235000012000 cholesterol Nutrition 0.000 description 15
- 238000008214 LDL Cholesterol Methods 0.000 description 14
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 13
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 12
- 229960005370 atorvastatin Drugs 0.000 description 12
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 12
- 230000002641 glycemic effect Effects 0.000 description 12
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 230000008859 change Effects 0.000 description 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 9
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 9
- 108010082126 Alanine transaminase Proteins 0.000 description 9
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 9
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 9
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 9
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 108010028554 LDL Cholesterol Proteins 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 229960000890 hydrocortisone Drugs 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 231100000304 hepatotoxicity Toxicity 0.000 description 6
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 5
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 5
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 5
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 5
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 5
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 5
- 230000003466 anti-cipated effect Effects 0.000 description 5
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 5
- 229960003765 fluvastatin Drugs 0.000 description 5
- 229960004844 lovastatin Drugs 0.000 description 5
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 5
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 229960002797 pitavastatin Drugs 0.000 description 5
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 5
- 229960002965 pravastatin Drugs 0.000 description 5
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 5
- 229960000672 rosuvastatin Drugs 0.000 description 5
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 5
- 229960002855 simvastatin Drugs 0.000 description 5
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 206010003119 arrhythmia Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- -1 20% greater Chemical class 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 206010013710 Drug interaction Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000036267 drug metabolism Effects 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 238000007449 liver function test Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 2
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- IZVFFXVYBHFIHY-SKCNUYALSA-N 5alpha-cholest-7-en-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC[C@H]21 IZVFFXVYBHFIHY-SKCNUYALSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000018452 Torsade de pointes Diseases 0.000 description 1
- 208000002363 Torsades de Pointes Diseases 0.000 description 1
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 108010024337 cortisol binding globulin Proteins 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229940029980 drug used in diabetes Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000011661 metabolic syndrome X Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- FRZJZRVZZNTMAW-UHFFFAOYSA-N n,n-diethyl-3-(hydroxymethyl)benzamide Chemical compound CCN(CC)C(=O)C1=CC=CC(CO)=C1 FRZJZRVZZNTMAW-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940064438 nizoral Drugs 0.000 description 1
- SOZOATLLFFVAPM-KAYWLYCHSA-N p-hydroxyatorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=C(O)C=C1 SOZOATLLFFVAPM-KAYWLYCHSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 231100000812 repeated exposure Toxicity 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 231100000607 toxicokinetics Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84896306P | 2006-10-02 | 2006-10-02 | |
| PCT/US2007/080186 WO2008042898A2 (en) | 2006-10-02 | 2007-10-02 | Ketoconazole enantiomer in humans |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ576569A true NZ576569A (en) | 2012-05-25 |
Family
ID=39269161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ576569A NZ576569A (en) | 2006-10-02 | 2007-10-02 | Ketoconazole enantiomer in humans |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9198906B2 (https=) |
| EP (1) | EP2076265A4 (https=) |
| JP (1) | JP2010505866A (https=) |
| AU (1) | AU2007303219A1 (https=) |
| BR (1) | BRPI0719835A2 (https=) |
| CA (1) | CA2664800A1 (https=) |
| IL (1) | IL197986A0 (https=) |
| NO (1) | NO20091593L (https=) |
| NZ (1) | NZ576569A (https=) |
| RU (1) | RU2009116632A (https=) |
| WO (1) | WO2008042898A2 (https=) |
| ZA (1) | ZA200902127B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1853266B1 (en) * | 2005-01-10 | 2011-10-12 | Cortendo AB (publ) | 2s,4r ketoconazole for treating diabetes, metabolic syndrome and other conditions |
| US20100280046A1 (en) * | 2006-01-10 | 2010-11-04 | Diobex, Inc. | Methods and Compositions for Treating Prostate Cancer, Benign Prostatic Hypertrophy, Polycystic Ovary Syndrome and Other Conditions |
| RU2009116632A (ru) | 2006-10-02 | 2010-11-10 | Кортендо Инвест, Аб (Se) | Энантиомер кетоконазола у людей |
| WO2015048311A1 (en) * | 2013-09-25 | 2015-04-02 | Cortendo Ab (Publ) | Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibitng cytochrome p450 inhibition |
| WO2016048984A1 (en) * | 2014-09-25 | 2016-03-31 | Cortendo Ab (Publ) | Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole |
| WO2020180784A1 (en) * | 2019-03-04 | 2020-09-10 | Strongbridge Dublin Limited | Methods of treating disease with levoketoconazole |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4144346A (en) | 1977-01-31 | 1979-03-13 | Janssen Pharmaceutica N.V. | Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles |
| US4503055A (en) | 1979-03-26 | 1985-03-05 | Janssen Pharmaceutica, N.V. | Derivatives of [4-(piperazin-1-yl-phenyloxymethyl)-1,3-dioxolan-2-ylmethyl]-1H-imidazoles and 1H-1,2,4-triazoles |
| US4814333A (en) | 1987-07-28 | 1989-03-21 | The Trustees Of Dartmouth College | Method for treatment of hypercortisolemic, depressed patients |
| US5432176A (en) | 1988-11-29 | 1995-07-11 | The John Hopkins University | Method of retarding the progression of chronic renal failure |
| WO1994014447A1 (en) * | 1992-12-22 | 1994-07-07 | Sepracor, Inc. | Methods and compositions of (-) ketoconazole for treating fungal yeast and dermatophyte infections |
| AU5851594A (en) | 1992-12-22 | 1994-07-19 | Georgetown University | Methods and compositions of (+) ketoconazole for treating fungal, yeast and dermatophyte infections |
| IL109728A0 (en) | 1993-05-28 | 1994-08-26 | Pfizer Res & Dev | Indoles |
| US5869255A (en) * | 1994-02-01 | 1999-02-09 | The Regents Of The University Of California | Probes labeled with energy transfer couples dyes exemplified with DNA fragment analysis |
| US6642236B1 (en) * | 1998-12-14 | 2003-11-04 | Cortendo Ab | Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis |
| SI0779810T1 (en) | 1994-08-09 | 2003-12-31 | Cortendo Ab | Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes |
| US5584790A (en) * | 1995-09-08 | 1996-12-17 | Beckman Instruments, Inc. | Variable inclination centrifugation assembly for rapid separation of blood |
| CA2240115A1 (en) | 1995-12-14 | 1997-06-19 | Wallace T. Ashton | Antagonists of gonadotropin releasing hormone |
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| US5994334A (en) * | 1997-02-05 | 1999-11-30 | University Of Maryland | Androgen synthesis inhibitors |
| SE9700642D0 (sv) | 1997-02-24 | 1997-02-24 | Kronvall Stefan Med Ab | Medel och sätt för förebyggande och behandling av det metabola syndromet |
| US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| AU749271B2 (en) | 1997-07-01 | 2002-06-20 | Agouron Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
| JP2002534512A (ja) | 1999-01-15 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 非ペプチドｇｌｐ−１アゴニスト |
| PT1171465E (pt) | 1999-03-29 | 2004-12-31 | Uutech Ltd | Analogos de petido inibidor gastrico e sua utilizacao para o tratamento de diabetes |
| AU4055400A (en) | 1999-04-02 | 2000-10-23 | Neurogen Corporation | Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics |
| WO2000069810A1 (en) | 1999-05-17 | 2000-11-23 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| GB9915625D0 (en) | 1999-07-02 | 1999-09-01 | Cortendo Ab | Method |
| RU2269354C2 (ru) | 1999-09-28 | 2006-02-10 | Байер Корпорейшн | Агонисты рецептора-3(r3) пептида-активатора гипофизарной аденилатциклазы(расар) и способы их фармакологического применения |
| GB0001449D0 (en) | 2000-01-21 | 2000-03-08 | Cortendo Ab | Compositions |
| US20020055512A1 (en) * | 2000-01-21 | 2002-05-09 | Cortendo Ab. | Compositions for delivery of a cortisol antagonist |
| WO2002000681A1 (en) | 2000-06-27 | 2002-01-03 | Aventis Pharma S.A. | 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase |
| GB0118300D0 (en) * | 2001-07-26 | 2001-09-19 | Cortendo Ab | Formulations |
| AU2002337119A1 (en) | 2001-09-21 | 2003-04-07 | Bayer Healthcare Ag | Regulation of human steroid 5-alpha reductase |
| JP2005512516A (ja) * | 2001-09-24 | 2005-05-12 | メルク エンド カムパニー インコーポレーテッド | スタチン薬物の組合せのスクリーニング方法および選択方法 |
| CA2461363A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors |
| BR0307595A (pt) * | 2002-02-07 | 2005-02-01 | Pfizer | Uso de inibidores de pde5 tal como sildenafil no tratamento de sìndrome de ovário policìstico |
| WO2004052390A1 (en) | 2002-12-11 | 2004-06-24 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
| WO2004080414A2 (en) * | 2003-03-12 | 2004-09-23 | Mullally John P | Composition and method for treating inflammations by reducing c-reactive protein |
| WO2005113516A1 (en) | 2004-05-14 | 2005-12-01 | Neurocrine Biosciences, Inc. | Uracil-type gonadotropin-releasing hormone receptor antagonists and methods related thereto |
| US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
| EP1853266B1 (en) | 2005-01-10 | 2011-10-12 | Cortendo AB (publ) | 2s,4r ketoconazole for treating diabetes, metabolic syndrome and other conditions |
| US20070116839A1 (en) * | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | High-Potency Sweetener Composition With C-Reactive Protein Reducing Substance and Compositions Sweetened Therewith |
| US20100280046A1 (en) * | 2006-01-10 | 2010-11-04 | Diobex, Inc. | Methods and Compositions for Treating Prostate Cancer, Benign Prostatic Hypertrophy, Polycystic Ovary Syndrome and Other Conditions |
| RU2009116632A (ru) | 2006-10-02 | 2010-11-10 | Кортендо Инвест, Аб (Se) | Энантиомер кетоконазола у людей |
| US9394290B2 (en) | 2010-10-21 | 2016-07-19 | Universitaet Des Saarlandes Campus Saarbruecken | Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases |
-
2007
- 2007-10-02 RU RU2009116632/15A patent/RU2009116632A/ru not_active Application Discontinuation
- 2007-10-02 CA CA002664800A patent/CA2664800A1/en not_active Abandoned
- 2007-10-02 AU AU2007303219A patent/AU2007303219A1/en not_active Abandoned
- 2007-10-02 EP EP07868351A patent/EP2076265A4/en not_active Withdrawn
- 2007-10-02 WO PCT/US2007/080186 patent/WO2008042898A2/en not_active Ceased
- 2007-10-02 US US12/443,531 patent/US9198906B2/en active Active
- 2007-10-02 ZA ZA200902127A patent/ZA200902127B/xx unknown
- 2007-10-02 JP JP2009531558A patent/JP2010505866A/ja active Pending
- 2007-10-02 NZ NZ576569A patent/NZ576569A/en not_active IP Right Cessation
- 2007-10-02 BR BRPI0719835-3A2A patent/BRPI0719835A2/pt not_active IP Right Cessation
-
2009
- 2009-04-05 IL IL197986A patent/IL197986A0/en unknown
- 2009-04-22 NO NO20091593A patent/NO20091593L/no not_active Application Discontinuation
-
2015
- 2015-11-18 US US14/944,258 patent/US20160067243A1/en not_active Abandoned
-
2018
- 2018-01-09 US US15/865,631 patent/US20180125841A1/en not_active Abandoned
-
2019
- 2019-03-13 US US16/351,797 patent/US20190209555A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010505866A (ja) | 2010-02-25 |
| EP2076265A2 (en) | 2009-07-08 |
| RU2009116632A (ru) | 2010-11-10 |
| BRPI0719835A2 (pt) | 2014-05-06 |
| US20180125841A1 (en) | 2018-05-10 |
| WO2008042898A2 (en) | 2008-04-10 |
| ZA200902127B (en) | 2010-07-28 |
| US9198906B2 (en) | 2015-12-01 |
| US20160067243A1 (en) | 2016-03-10 |
| WO2008042898A3 (en) | 2008-10-23 |
| NO20091593L (no) | 2009-04-22 |
| IL197986A0 (en) | 2009-12-24 |
| EP2076265A4 (en) | 2010-09-22 |
| US20190209555A1 (en) | 2019-07-11 |
| CA2664800A1 (en) | 2008-04-10 |
| WO2008042898A9 (en) | 2008-09-04 |
| AU2007303219A1 (en) | 2008-04-10 |
| US20100093755A1 (en) | 2010-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190209555A1 (en) | Ketoconazole enantiomer in humans | |
| US6369103B1 (en) | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor | |
| JP5358095B2 (ja) | 糖尿病、メタボリック症候群、および他の状態を治療するための方法および組成物 | |
| US20110288110A1 (en) | Methods for treating disorders associated with hyperlipidemia in a mammal | |
| JP2016053057A (ja) | 糖尿病の合併症のための療法 | |
| AU2001242985B2 (en) | New combination of a betablocker and a cholesterol-lowering agent | |
| Sunkara et al. | Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects | |
| Chou et al. | Effect of 1PC111, a fixed-dose combination of pitavastatin and ezetimibe, versus pitavastatin or ezetimibe monotherapy on lipid profiles in patients with hypercholesterolemia or mixed dyslipidemia: A randomized, double-blind, multicenter, Phase III study | |
| JP2021535136A (ja) | 心血管疾患及び関連する状態を有する患者を処置するための併用薬製剤 | |
| Sharif et al. | The effect of rosuvastatin on insulin sensitivity and pancreatic beta-cell function in nondiabetic renal transplant recipients | |
| JP6227535B2 (ja) | 脂質異常症の予防又は治療薬 | |
| RU2233162C2 (ru) | Лекарственные комбинации, включающие (е)-7-[-4-(4-фторфенил)-6-изопропил-2-[-метил(метилсульфонил)амино]- пиримидин-5-ил](3r,5s)-3,5-дигидроксигепт-6-еноевую кислоту и ингибитор, индуктор или субстрат изофермента р450-3а4 | |
| Martell-Claros et al. | Manidipine for hypertension not controlled by dual therapy in patients with diabetes mellitus: a non-comparative, open-label study | |
| US20090137632A1 (en) | Compositions And Methods For Treating Dyslipidemia | |
| KR20030010750A (ko) | 베타블록커 및 임의로 콜레스테롤 저하제를 포함하는신규한 제제 | |
| Prasad et al. | Lack of interaction between modified-release fluvastatin and amlodipine in healthy subjects | |
| US20090275551A1 (en) | Fluvastatin for the treatment of patients with a history of muscle related side effects with other statins | |
| Xue | Pharmacokinetics/pharmacodynamics of selected analgesics in dental patients | |
| HK1118449B (en) | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | |
| ZA200105838B (en) | Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-YL] (3R,5S) -3,5-dihydroxyhept-6-enoic acid and an inhibitor inducer or substrate of P450 isoenzyme 3A4. | |
| HK1051325B (en) | New combination of a betablocker and a cholesterol-lowering agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2015 BY BALDWINS INTELLECTUAL PROPERTY Effective date: 20150220 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2016 BY LEA Effective date: 20160324 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2017 BY LEA SKYLLERSTEDT Effective date: 20160921 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2018 BY CPA GLOBAL(PATRAFEE) AB Effective date: 20171011 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2019 BY CPA GLOBAL(PATRAFEE) AB Effective date: 20180919 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2020 BY CPA GLOBAL(PATRAFEE) AB Effective date: 20190920 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2021 BY CAMILLA WELLIN Effective date: 20210319 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2022 BY CAMILLA WELLIN / CPA GLOBAL CLARIVATE Effective date: 20211207 |
|
| LAPS | Patent lapsed |